EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension

Yu Lin, Yuanqi Su, Zhongjie Cheng, Bing Zhu, Qi Pei iD

Clinical Pharmacokinetics · 2025-07 · 64 (7) · 973-986

DOI: 10.1007/s40262-025-01525-0 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 28.05.2025. Verfasst von Yu Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chongqing Medical and Pharmaceutical College, Chongqing, 401331, China. Hauptthemen laut MEDLINE: Hypertension, Pulmonary, Antihypertensive Agents, Vasodilator Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 86 Literaturangaben. Gefördert von: Chongqing Municipal Education Commission, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pulmonary hypertension (PH) is a serious condition characterized by elevated blood pressure in the pulmonary arteries. Current treatment approaches mainly focus on using vasodilator agents to reduce pulmonary blood pressure and improve blood flow. Inhalation treatments offer targeted delivery to the lungs, improving efficacy and reducing systemic side effects. Understanding the pharmacokinetics (PK) of the molecules used in the inhalation treatment is crucial for dose optimization and drug product development. This review examines the clinical PK characteristics of key inhaled PH drugs (approved and investigational agents), including epoprostenol, iloprost, treprostinil, vardenafil, imatinib, seralutinib, MK-5475, milrinone, and sodium nitrite. We provide detailed analyses of their PK parameters and explore how disease conditions, inter-subject variability, and inhaled formulations and devices impact clinical PK characteristics. Future research would focus on how disease-specific factors affect drug behavior and the prediction of pulmonary drug concentrations. This will support more precise drug delivery and personalized treatment strategies for PH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hypertension, PulmonaryAntihypertensive AgentsVasodilator AgentsHumansAdministration, Inhalation

Substanzen

Antihypertensive AgentsVasodilator Agents

Autor:innen und Institutionen

  • Chongqing Medical and Pharmaceutical College, Chongqing, 401331, China.
  • Respirent Pharmaceuticals Co., Ltd, 5 Yuntu Road, Chongqing, 400714, China.
  • Respirent Pharmaceuticals Co., Ltd, 5 Yuntu Road, Chongqing, 400714, China. bing.zhu@respirent.cn.
  • Department of Pharmacy, The Third Xiangya Hospital, Central South University, 172 Tongzipo Road, Changsha, 410013, Hunan, China. peiqi1028@126.com.

ORCID-Profile: Qi Pei

Förderung

  • Chongqing Municipal Education Commission
  • National Natural Science Foundation of China

Zitieren

APA

Lin, Y., Su, Y., Cheng, Z., Zhu, B., & Pei, Q. (2025). Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension. Clinical Pharmacokinetics, 64(7), 973-986. https://doi.org/10.1007/s40262-025-01525-0

Vancouver

Lin Y, Su Y, Cheng Z, Zhu B, Pei Q. Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension. Clinical Pharmacokinetics. 2025;64(7):973-986. doi:10.1007/s40262-025-01525-0

BibTeX
@article{Lin2025,
  author = {Lin, Yu and Su, Yuanqi and Cheng, Zhongjie and Zhu, Bing and Pei, Qi},
  title = {Clinical Pharmacokinetics of Inhaled Drugs for Pulmonary Hypertension},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  volume = {64},
  number = {7},
  pages = {973--986},
  doi = {10.1007/s40262-025-01525-0}
}
Kostenlos starten →